Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 5—May 2011
Dispatch

Probable Non–Vector-borne Transmission of Zika Virus, Colorado, USA

Brian D. FoyComments to Author , Kevin C. Kobylinski, Joy L. Chilson Foy, Bradley J. Blitvich, Amelia Travassos da Rosa, Andrew D. Haddow, Robert S. Lanciotti, and Robert B. Tesh
Author affiliations: Author affiliations: Colorado State University, Fort Collins, Colorado, USA (B.D. Foy, K.C. Kobylinski); Poudre Valley Hospital, Fort Collins (J.L.C. Foy); Iowa State University, Ames, Iowa, USA (B.J. Blitvich); University of Texas Medical Branch, Galveston, Texas, USA (A. Travassos da Rosa, A.D. Haddow, R.B. Tesh); Centers for Disease Control and Prevention, Fort Collins (R.S. Lanciotti)

Main Article

Table A1

Serologic results for 3 patients in whom symptoms of arboviral illness developed, northern Colorado, USA, 2008*

Serum sample Viruses/viral antigens tested
GETV CHIKV SINV ZIKV DENV1 DENV2 DENV3 DENV4 YFV WNV UGSV SLEV TAHV JCV LACV
Hemagglutination inhibition test
Pt1a 0 0 NT 5,120 2,560 640 2,560 2,560 5,120 2,560 1,280 NT 0 NT NT
Pt1c 0 0 NT 5,120 1,280 320 1,280 1,280 2,560 1,280 1,280 NT 0 NT NT
Pt2a 0 0 NT 1,280 160 80 320 320 1,280 160 160 NT 0 NT NT
Pt2c 0 0 NT 2,560 160 80 320 320 1,280 160 160 NT 0 NT NT
Pt3a 0 0 NT 0 0 0 0 0 0 0 0 NT 0 NT NT
Pt3c
0
0
NT
320
0
0
0
0
0
0
0
NT
0
NT
NT
Plaque-reduction neutralization test
Pt1a NT <10 <10 10,240 80 1,280 320 160 >20,480 <10 NT 80 <10 NT NT
Pt1c NT NT NT >40,960 160 230 320 320 >40,960 160 NT NT NT NT NT
Pt2a NT NT NT 10,240 <20 80 80 40 5,120 NT NT NT NT NT NT
Pt2c NT NT NT 40,960 80 160 160 160 20,480 80 NT NT NT NT NT
Pt3a NT NT NT 10 <10 <10 <10 <10 <10 <10 NT <10 NT <10 <10
Pt3c
NT
NT
NT
1,280
<10
<10
<10
<10
<10
<10
NT
NT
NT
NT
NT
Complement fixation test
Pt1a NT NT NT 64/8 NT NT NT NT 64/8 NT NT NT NT NT NT
Pt1c NT NT NT 128/32 NT NT NT NT 64/8 NT NT NT NT NT NT
Pt2a NT NT NT 16/8 NT NT NT NT 16/8 NT NT NT NT NT NT
Pt2c NT NT NT 32/32 NT NT NT NT 16/8 NT NT NT NT NT NT
Pt3a NT NT NT 0 NT NT NT NT 0 NT NT NT NT NT NT
Pt3c NT NT NT 16/8 NT NT NT NT 0 NT NT NT NT NT NT

*Togaviridae: GETV, Getah virus; CHIKV, chikungunya virus; SINV, Sindbis virus; Flaviviridae: ZIK, Zika virus; DENV, dengue virus; YFV, yellow fever virus; WNV, West Nile virus; UGSV, Uganda S virus; SLEV, St. Louis encephalitis virus; Bunyaviridae: TAHV, Tahyna virus; JCV, Jamestown Canyon virus; LAC, La Crosse virus; pt1, 2, and 3, patients 1, 2, and 3, respectively; a and c, acute-phase and convalescent-phase serum samples, respectively; NT, not tested. Hemagglutination test, numbers are reciprocal of serum dilution inhibiting 4 units of antigen; 0 = negative reaction at a 1:20 dilution. Plaque-reduction neutralization test, numbers refer to neutralizing antibody titers with a 90% cutoff value: titers > positive control serum samples are indicated in boldface. Complement fixation tests, numbers refer to reciprocal of serum titer/reciprocal of antigen titer; 0, negative reaction at <8/<8.

Main Article

Page created: August 14, 2011
Page updated: August 14, 2011
Page reviewed: August 14, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external